Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara
Portfolio Pulse from
Teva Pharmaceuticals and Alvotech have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the US.
February 21, 2025 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Johnson & Johnson may face increased competition in the US market for its autoimmune drug Stelara due to the launch of a biosimilar by Teva and Alvotech.
The introduction of a biosimilar to Stelara could lead to reduced market share and revenue for J&J, negatively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 60
POSITIVE IMPACT
Alvotech, in partnership with Teva, has launched a biosimilar to J&J's Stelara in the US, marking a significant step in its product offerings.
Alvotech's collaboration with Teva to launch a biosimilar to Stelara can enhance its reputation and market presence, likely benefiting its stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Teva Pharmaceuticals has launched a biosimilar to J&J's Stelara in the US, which could enhance its market position in the autoimmune drug sector.
The launch of a biosimilar to a major drug like Stelara can increase Teva's market share and revenue in the autoimmune sector, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80